Borrelia Burgdorferi Bacterin
The only Lyme vaccine with a traditional isolate targeted at OspA and a unique isolate proven to induce high levels of borreliacidal antibodies to OspC.1
Features and benefits
The only Lyme vaccine designed to target the 2 key outer surface proteins (Osps) involved in disease transmission for a full level of protection.
- Proven to induce borreliacidal antibodies that bind to OspA and OspC, forming a complex that attacks the cell membrane and kills Borrelia burgdorferi1,2
- Proven to help prevent clinical disease such as arthritis2
- Highly effective: no serologic evidence of exposure to B. burgdorferi2
- For the vaccination of healthy dogs as an aid in the prevention of clinical disease and subclinical arthritis associated with Borrelia burgdorferi
- Recommended for use in healthy dogs 8 weeks of age or older
Proven safe and well tolerated in a field safety trial of more than 600 dogs1
- Less than 1% of dogs experienced vaccine-related adverse reactions
- 99.3% reaction-free
- No dogs removed from the study
- Since 2009, Nobivac Lyme has been safely administered to over 2 million dogs
Dosage and administration
- Subcutaneous injection
- Two 1-mL doses given 2 to 4 weeks apart
- Last dose may be given at 12 weeks of age
- Annual revaccination with 1 dose is recommended
- Available in a 25 x 1-mL dose
For further information, including complete directions and warnings, please see the product label.
- Data on file, Merck Animal Health.
- LaFleur RL, Dant JC, Wasmoen TL, et al. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin Vaccine Immunol. 2009;16(2):253–259.